av Drig Manufacturer Report											
tion	Data element	Field type	Drug #1	Drug #2	Drug #3	Drug #4	Drug #5	Drug #6	Drug #7	Drug #8	Please add columns as needed
Drug identification	National drug code (11-digit NDC)	Numeric	66302030002	66302030202	66302031002	66302032502	66302035002	66302036128	66302036256	66302036384	
	Drug name	Text	Orenitram 0.125MG Tab 10 ct. Blister Pack	Orenitram 0.25MG Tab 10 ct. Blister Pack	Orenitram 1.0MG Tab 10 ct. Blister Pack	Orenitram 2.5MG Tab 10 ct. Blister Pack	Orenitram SMG Tab 10 ct. Blister Pack	Orenitram Titration Kit 7-Blister Card Pack 0.125mg and 0.25mg Month 1	Orenitram Titration Kit 7-Blister Card Pack 0.125mg and 0.25mg Month 2	Orenitram Titration Kit 7-Blister Card Pack 0.125mg and 0.25mg and 1 mg Month 3	
	Decolption of the marketing and pricing plans used in the bursch of the new drug in the United States and incernationally	Test	number of patients in the US annually. United	maticate broken ja paratesian a species and society in interm of cital catoronis and quality of IR, angeleng in ref. IR, and saving generatesian the other parate in the species of the species of the species of the species of the species of the species of the species of the species of the species of the species of the species paratesian species of the species of the species of the paratesian species of the species of the species of the species species of the species of the species of the species species of the s	number of patients in the US annually. United	Until Therparentics consider multiple tattow when there is a far part for a models, including the shorts the society - in term of clinical automate and quality of fits, and any second second second second second second the handhard second second second second second and quality of fits, and second second second second and quality of fits, and second second second second second second second second second second second second second second second second second transport of the second second second second methods and second second second second transport of the second second second second transport of the second second second second transport of the second second second particles to provide with from symptom as set y ₀ as transmost second second second second transports and the second second second transport of the second second second transports and the second second second transports and the second second second transports are second as the second second transport of the second second second second transports are set of the second second second transports are set of the second second second second transport second second and provide intermetters should transport the second second second second second transport second second second second second second transport second s	medicine brings to patients, healthcare systems and society - in terms of chinal outcomes and quality of flo, longwiry of flo, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: Object preach-investment costs, Medical and patient service costs (which may or may not include patient assistance organism and capatibil-investment costs associated with manufacturing, storage and supply).	Unlied Transportics consisten multiple factors when there are particle and the second tech handhow and a second particles to provide second second second second particles to provide second second second second particles to provide second second second particles to provide second second second second second second second second second particles to provide second these second second particles to provide second these second second second second second second second second particles to provide second these second second second second second second second second second second second second second second particles to provide second these second second second second second second second second second second second second second second particles to provide second these second particles to provide second these second second second second second second second second second second second second second second second second second s	Untel Theoperative consider multiple factors when there is all part of the stands, including leaders is used to stand the stands of the stands of the stands of the stands of the stands of the stands of the stands of the stands of the stands of the stand of the handling changes reasoning sources of our handling changes reasoning stands and a stands of the stands of the handling changes reasoning sources of the stands of the handling changes reasoning stands of the stands of the handling changes reasoning sources of the stands of the handling changes reasoning stands of the stands of the handling changes reasoning stands of the stands of the handling changes reasoning stands of the stands of the stands of the stands of the stands of the handling the stands of the stands of the stands of the stands of the stands of the stands of the handling the stands of the s	Linket Throught is consider multiple factors when there is the proof to enclose, including the burntless incomes in terms of cincil automation and quality of Kin- geoperty of Kin, and single geometration for other parts of the hardness regions and a single of the parts and the hardness regions and a single single single single single and quality of Kin- sense and the single single single single single single single constraints and a single single single single single single single constraints and single si	
	Estimated volume of patients who may be prescribed the drug	Numeric	This information is confidential and proprietary, and not publicly available or within the public domain.		This information is confidential and proprietary, and not publicly available or within the public domain.	This information is confidential and proprietary, and not publicly available or within the public domain.	This information is confidential and proprietary, and not publicly available or within the public domain.	This information is confidential and proprietary, and not publicly available or within the public domain.	This information is confidential and proprietary, and not publicly available or within the public domain.	This information is confidential and proprietary, and not publicly available or within the public domain.	
	Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval	Text	Neither is applicable	Neither is applicable	Neither is applicable	Neither is applicable	Neither is applicable	Neither is applicable	Neither is applicable	Neither is applicable	
	Date and price of acquisition if the drug was not developed by the manufacturer	Text	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	